I

IQVIA

Analytics, technology, and clinical research services.

Operations Specialist Manager

Full-TimePosted on 10/1/2026Deadline 10/30/26
No salary listed
Mid
Bachelor's
Barcelona, Spain+2 moreMore locations: Madrid, Spain | Dublin, Ireland
In Person

About the job

Requirements
  • A bachelor's degree in a scientific or healthcare discipline or allied life sciences, or an equivalent combination of education, training, and experience.
  • Up to 5 years of relevant experience, including up to 3 years of pharmacovigilance experience.
  • Excellent knowledge of medical terminology.
  • In-depth knowledge and understanding of the applicable safety database and other internal or client applications.
  • In-depth knowledge and understanding of applicable global, regional, and local clinical research regulatory requirements.
  • Excellent organizational and time-management skills, with attention to detail and accuracy.
  • Ability to demonstrate high-quality standards.
  • Excellent working knowledge of Microsoft Office and web-based applications.
  • Effective project management and leadership skills.
  • Effective mentoring and coaching skills.
  • Excellent verbal and written communication skills.
  • Self-motivation, flexibility, and receptiveness to changing process demands.
  • Willingness and aptitude to learn new skills across safety service lines.
  • Ability to work independently and autonomously within policies and practices.
  • Ability to multitask, meet strict deadlines, and manage competing priorities.
  • Ability to identify and prioritize tasks and delegate to team members.
  • Ability to establish and maintain effective communication and working relationships with coworkers, managers, and clients.
  • Ability to work as a team member and contribute to team goals.
  • Sound judgment and decision-making skills.
  • Ability to work effectively on multiple projects simultaneously, organize own workload, and manage team priorities.
  • Ability to ensure the quality of deliverables according to agreed terms.
  • Demonstration of IQVIA core values in daily tasks.
  • Ability to plan workload based on available capacity and reprioritize as workload fluctuates.
  • Ability to negotiate and find a mutually satisfactory position with stakeholders.
Responsibilities
  • Process safety data according to applicable regulations, guidelines, standard operating procedures, and project requirements.
  • Perform pharmacovigilance activities as required by projects, including collecting and tracking incoming adverse events and endpoint information.
  • Determine the initial or updated status of incoming events.
  • Enter data into databases.
  • Code adverse events and products, write narratives, perform literature-related activities and quality reviews, assist with reconciliation and case closure, coordinate translations, and create, maintain, and track cases according to project timelines and plans.
  • Perform activities related to adjudication as applicable.
  • Assess safety data for reportability to relevant authorities; track reportable cases and report them to regulatory authorities, ethics committees, institutional review boards, investigators, and oversight groups within legislative timelines and required formats; liaise with stakeholders to facilitate expedited reporting.
  • Liaise with the manager regarding regulatory tracking requirements and electronic reporting.
  • When acting as functional lead, define, set up, and document safety reporting procedures aligned with IQVIA or customer standard operating procedures, including coordinating with Lifecycle Safety Systems or customer IT teams to establish regulatory reporting rules and gateways and document appropriate reporting delegation.
  • Contribute expertise to or lead assigned deliverables in safety publishing, risk management, safety surveillance, medical information, or other service lines as appropriate.
  • Ensure adherence to compliance, quality, productivity, and delivery standards for assigned projects.
  • Build a collaborative team environment, lead by example, train and mentor less experienced team members and operations staff, and back up the Operations Manager when needed.
  • Provide technical and process information to Safety Management and operational team members on project-specific issues.
  • Provide operational oversight and maintain understanding of the team’s status, metrics, productivity, and initiatives.
  • Maintain a thorough understanding of the project protocol, therapeutic indication, budget, and scope of work for assigned projects.
  • Set up and maintain project files, standard templates, electronic forms, databases, and workflows as required by the project.
  • Maintain effective team and project communications, including regular feedback to the operations team manager and relevant stakeholders about project metrics, out-of-scope work challenges, issues, and successes.
  • Provide feedback to junior team members on project performance.
  • Read and acknowledge required IQVIA and customer standard operating procedures; complete and document required training on time; maintain a complete individual training plan and up-to-date training transcripts.
  • Participate in or lead training across safety process service offerings.
  • Participate in working groups to implement new initiatives and identify and implement process efficiencies.
  • Liaise with functional team members, including project management, clinical, and data management, and healthcare professionals such as investigators, medical monitors, site coordinators, and designees to address project-related issues.
  • Attend project team meetings and provide regular feedback to the operations team manager on operational project metrics, out-of-scope work challenges, issues, and successes.
  • Liaise with clients about day-to-day activities as needed.
  • Contribute to achievement of departmental goals.
  • Perform other duties as assigned.
  • Comply fully with people practices and processes.

About the company

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Get referred to IQVIA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 8.7%; management raised full-year revenue and EPS guidance.
  • R&DS bookings jumped 19.3% in Q2 2026, lifting backlog to $34.2 billion.
  • Nineteen of the top 20 pharma firms adopted IQVIA’s AI and analytics stack.

What critics are saying

  • Debt reached $15.999 billion on June 30, 2026; refinancing costs rose September 2026.
  • AbbVie, Pfizer, and peers can shift trials to Medpace, ICON, or internal platforms.
  • If AI claims disappoint regulators or clients, IQVIA’s premium multiples compress fast.

What makes IQVIA unique

  • IQVIA’s September 3, 2026 Predictive Clinical Development links data, AI, and trial operations.
  • Its Prime and Partner site network and proprietary healthcare data create sticky sponsor workflows.
  • The 2016 IMS Health merger gives IQVIA unmatched clinical, commercial, and real-world datasets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↓ -1%

2 year growth

↑ 0%
Diagnostics World News
Sep 24th, 2026
IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education.

IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education. IQVIA MedTech is highlighting its Surgical Collaboration Platform (SCP), a purpose-built platform designed to help MedTech organizations coordinate and track peer-to-peer surgeon education across the engagement lifecycle. As medical device companies introduce increasingly sophisticated devices, robotic systems, implants and surgical tools, clinician education can play a critical role in supporting technology adoption. However, the infrastructure behind these programs can remain fragmented, with education teams coordinating faculty availability, learner requests, scheduling, credentialing and documentation across spreadsheets, email and disconnected systems. The IQVIA MedTech Surgical Collaboration Platform is designed to bring those activities into a more connected workflow. The platform helps clinicians and education teams manage surgeon requests, credentialing, host-surgeon identification, faculty and site availability, scheduling, documentation, training completion and program reporting. The platform is intended to address an infrastructure challenge that can become increasingly complex as new technologies reach additional surgeons, sites and markets. By creating greater visibility across the education journey, IQVIA aims to help MedTech organizations more effectively coordinate and scale surgeon-to-surgeon education.

Yahoo Finance
Sep 16th, 2026
IQVIA stock surges 60% in 6 months on strong organic growth and AI adoption

IQVIA stock has risen 60.1% over the past six months, outpacing the industry's 4.1% return and the S&P 500's 14% rally. The company's strong performance is driven by accelerating organic growth, with second-quarter 2026 revenue rising 6% year over year. Research & Development Solutions grew 7% organically, whilst the commercial side increased 5%. IQVIA's R&DS net new bookings jumped 19.3% year over year in Q2 2026, producing a book-to-bill ratio of 1.22. Backlog reached $34.2 billion at the end of June. The company has deployed 294 AI agents across 90 use cases. Nineteen of the top 20 pharmaceutical companies have adopted IQVIA's solutions, strengthening its competitive position.

Jardal Paintball
Sep 9th, 2026
IQVIA prices $2B senior notes offering to refinance debt and credit facility

IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.

Hyman, Phelps & McNamara, P.C.
Sep 4th, 2026
HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18).

HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog

StockTitan
Sep 3rd, 2026
IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster.

IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster. IQVIA introduces an AI-driven clinical development platform that reports sizable time savings from study startup through data cleaning and between trial phases. (Positive) See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/03/2026 - 01:15 PM RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results: * 33% faster study startup * 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with 42% higher enrollment rates * 50% faster data cleaning * 45%+ reduced time between trial phases IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI(R) with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows. "At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality - compressing timelines, accelerating decisions and speeding medicines to market." IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities: * Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment. * Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment. * Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks. IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Key terms. agentic workflows technical data cleaning technical database locks technical